MENU
+Compare
CTNM
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$12.40
Change
-$0.28 (-2.21%)
Capitalization
463.19M

CTNM Contineum Therapeutics Forecast, Technical & Fundamental Analysis

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need... Show more

CTNM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CTNM with price predictions
Dec 24, 2025

Momentum Indicator for CTNM turns positive, indicating new upward trend

CTNM saw its Momentum Indicator move above the 0 level on December 24, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 18 cases where CTNM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CTNM just turned positive on December 22, 2025. Looking at past instances where CTNM's MACD turned positive, the stock continued to rise in of 13 cases over the following month. The odds of a continued upward trend are .

CTNM moved above its 50-day moving average on December 08, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CTNM crossed bullishly above the 50-day moving average on December 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTNM advanced for three days, in of 85 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 52 cases where CTNM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CTNM moved out of overbought territory on December 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTNM broke above its upper Bollinger Band on December 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.567) is normal, around the industry mean (26.541). P/E Ratio (26.395) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (10.101) is also within normal values, averaging (311.015).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CTNM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTNM is expected to report earnings to rise 44.44% to -64 cents per share on March 05

Contineum Therapeutics CTNM Stock Earnings Reports
Q4'25
Est.
$-0.65
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.34
Q1'25
Missed
by $0.20
Q4'24
Missed
by $0.11
The last earnings report on October 30 showed earnings per share of -44 cents, beating the estimate of -60 cents. With 34.30K shares outstanding, the current market capitalization sits at 463.19M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 333-5280
Employees
31
Web
https://www.contineum-tx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WPVLX30.880.10
+0.32%
Weitz Multi Cap Equity-Investor Cl
THOCX45.060.11
+0.24%
Thornburg Global Opportunities C
FTAWX14.480.03
+0.21%
Fidelity Advisor Asset Manager 20% A
HFSFX17.170.01
+0.06%
Hartford Schroders Intl Cntrrn Val F
HWTIX11.76-0.01
-0.08%
Hotchkis & Wiley Intl Sm Cp Dvsfd Val I

CTNM and Stocks

Correlation & Price change

A.I.dvisor tells us that CTNM and VYGR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTNM and VYGR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTNM
1D Price
Change %
CTNM100%
+3.01%
VYGR - CTNM
29%
Poorly correlated
+2.01%
CCCC - CTNM
28%
Poorly correlated
+2.97%
TNGX - CTNM
28%
Poorly correlated
+1.99%
MREO - CTNM
27%
Poorly correlated
+0.44%
SLN - CTNM
27%
Poorly correlated
-2.07%
More